Sugi Predict

Sugi Predict / Compounds / SCHEMBL160221

SCHEMBL160221

SCHEMBL160221

NC(=O)c1cccc(F)c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 3/20 0.48
▸ CES1 P23141 3/20 0.48
▸ BCHE P06276 1/20 0.48
▸ ALB P02768 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ ALOX15 P16050 1/20 0.43
▸ PARP1 P09874 3/20 0.43
▸ PBRM1 Q86U86 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ DGAT1 O75907 1/20 0.42
▸ METAP2 P50579 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ G6PD P11413 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40536 0.84 ALDH1A1 (0.54) ALDH1A1MAPTKDM4EHPGDTSHR
SCHEMBL161951 0.83 ALB (0.61) CES2CES1BCHEALBALDH1A1
SCHEMBL4608420 0.81 KMT2A (0.49) CES2CES1BCHEALBALDH1A1
SCHEMBL30515953 0.81 KMT2A (0.49) CES2CES1BCHEALBALDH1A1
SCHEMBL203112 0.80 CES2 (0.68) CES2CES1BCHEALBALDH1A1
SCHEMBL29528396 0.80 CES2 (0.68) CES2CES1BCHEALBALDH1A1
SCHEMBL80721 0.79 CES2 (0.65) CES2CES1BCHEALDH1A1MAPT
SCHEMBL29482931 0.79 CES2 (0.65) CES2CES1BCHEALDH1A1MAPT
SCHEMBL2646259 0.78 CES2 (0.48) CES2CES1BCHEALBALDH1A1
SCHEMBL11266406 0.78 CES2 (0.54) CES2CES1BCHEALBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118084678-B Preparation method of 2-bromo-6-fluoroaniline 长沙唯楚医药科技有限公司 2024-09-06 — — CN claimed
CN-118084678-A Preparation method of 2-bromo-6-fluoroaniline 长沙唯楚医药科技有限公司 2024-05-28 — — CN claimed
CN-114773277-B Citral nitrogen-containing derivative, and preparation method and application thereof 江西省林业科学院 2023-11-28 — — CN claimed
CN-114773277-A Citral nitrogen-containing derivative and preparation method and application thereof 江西省林业科学院 2022-07-22 — — CN claimed
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 — — EP disclosed
CN-118084678-B Preparation method of 2-bromo-6-fluoroaniline 长沙唯楚医药科技有限公司 2024-09-06 — — CN disclosed
CN-118084678-B Preparation method of 2-bromo-6-fluoroaniline 长沙唯楚医药科技有限公司 2024-09-06 — — CN disclosed
CN-112469707-B Preventive or therapeutic agent for spinal muscular atrophy 利伯纳生物科学株式会社 2024-06-21 — — CN disclosed
US-12012410-B2 Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy REBORNA BIOSCIENCES, INC. (JP) 2024-06-18 — — US disclosed
CN-118084678-A Preparation method of 2-bromo-6-fluoroaniline 长沙唯楚医药科技有限公司 2024-05-28 — — CN disclosed
CN-118084678-A Preparation method of 2-bromo-6-fluoroaniline 长沙唯楚医药科技有限公司 2024-05-28 — — CN disclosed
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2024-05-28 — — US disclosed
US-20080182852-A1 ANTHRANILAMIDE INHIBITORS OF AURORA KINASE GLAXOSMITHKLINE LLC 2008-07-31 — — US disclosed
WO-2008092049-A1 ANTHRANILAMIDE INHIBITORS OF AURORA KINASE SMITHKLINE BEECHAM CORPORATION (US) 2008-07-31 — — WO disclosed
WO-2008051547-A1 FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2008-05-02 — — WO disclosed
WO-2008002596-A2 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2008-01-03 — — WO disclosed
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 — — US disclosed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 — — EP disclosed
US-5030727-A Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile BASF AKTIENGESELLSCHAFT (DE) 1991-07-09 — — US disclosed
EP-0263523-A2 Process for the preparation of thiazolo [2,3-b] quinazolones BASF Aktiengesellschaft (DE) 1988-04-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182852-A1 ANTHRANILAMIDE INHIBITORS OF AURORA KINASE AURKA, AURKC, AURKB CES2 4692/4885CES1 3623/4885BCHE 4003/4885
US-12012410-B2 Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy SMN1; SMN2, HDAC5, PUM1 CES2 4491/4885CES1 4614/4885BCHE 3227/4885
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 CES2 2018/4885CES1 2542/4885BCHE 3875/4885
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof PARP11, PARP1, CD38 CES2 1829/4885CES1 2172/4885BCHE 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.